Highlights include the company’s significant progress in 2022 to create a more sustainable R&D model and advance potential new medicines to patients.

Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today announced the release of its second annual Environmental, Social and Governance (ESG) Report. The report highlights the company’s approach, practices and goals in several important areas such as its commitment to patients, social and community impact, people and culture, environmental sustainability, and governance.

“As a company focused on using cutting-edge technology to find solutions to some of the most complex and pressing problems in biotechnology, we have the opportunity to create massive positive impact in the world and build an incredible business to drive it,” said Chris Gibson, Ph.D., Co-Founder and Chief Executive Officer at Recursion. “In our second annual ESG report, we outline how our work in 2022 to industrialize drug discovery is in direct support of our vision to create a more sustainable future – not only to benefit patients, but also our employees, partners, communities, and the broader healthcare and technology innovation ecosystems.”

Since publishing its inaugural ESG report last year, Recursion has received several recognitions for its commitment to excellence in ESG. Institutional Shareholder Services (ISS) awarded Recursion a Prime Rating for ESG performance in 2022, which recognizes companies with ESG performance above a sector-specific threshold and is defined by ISS as “absolute best in class.” Additionally, as of October 2022, Recursion was ranked 98 out of over 850 companies (approximately top 10%) in the pharmaceutical category by Morningstar Sustainalytics, which gives an in-depth analysis of a company’s ESG performance and compares it to industry peers. In February 2023, Recursion received an MSCI ESG Rating of A.

Recursion’s ESG Report is guided by key ESG frameworks, notably the standards of the Sustainability Accounting Standards Board (SASB) and the United Nations Sustainable Development Goals (UN SDGs). You can learn more about Recursion’s approach to ESG and download a copy of the report at www.Recursion.com/esg.

About Recursion

Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.

Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montreal and the San Francisco Bay Area. Learn more at www.Recursion.com, or connect on Twitter and LinkedIn.

Forward-Looking Statements

This document contains information that includes or is based upon “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding early and late stage discovery, preclinical, and clinical programs; licenses and collaborations; prospective products and their potential future indications and market opportunities; Recursion OS and other technologies; business and financial plans and performance; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K. All forward-looking statements are based on management’s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.